Oxurion (OXUR.BR) traded flat 0 % during a 24 hours period ending at 02:37 AM Central Europe on Tuesday 27th. One Oxurion stock can currently be bought for about EUR 0 on popular exchanges. Current supply of Oxurion stocks is 232 mn. Oxurion has a current market capitalization of EUR 185.6 k and approximately EUR 3.2 k worth of Oxurion was traded on exchanges in the last 24 hours. Since last month end, Oxurion has traded -55.56 % down. Simple moving average of last 200 days is at EUR 0. The highest price of past 52 weeks was recorded at EUR 0.02 on 10/28/2025. 52 weeks low was at EUR 0 on 10/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Metrics Balance (MLMIB.PA) traded flat 0 % and now trades at EUR 0.03. Metrics Balance has a market capitalisation of EUR 144.9 k.

  • Mdxhealth (O6C1.F) traded down -60 % and now trades at EUR 0. Mdxhealth has a market capitalisation of EUR 190.8 k.

  • Oxford Biodynamics (OBD.L) traded up 4.55 % and now trades at GBX 0.12. Current market capitalisation for Oxford Biodynamics is GBX 20.7 mn.

  • Chimeric Therapeutics (CHM.AX) traded down -40 % and now trades at AUD 0.01. Chimeric Therapeutics has a market capitalisation of AUD 354.4 k.

About Oxurion

Oxurion NV is an integrated biopharmaceutical company that specializes in addressing unmet clinical needs in ophthalmology both nationally and internationally. The company’s lead product, JETREA, is used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. Additionally, Oxurion NV is developing THR-317, a placental growth factor (PIGF) neutralizing monoclonal antibody, currently in Phase I/II clinical study for the treatment of diabetic macular edema (DME) or diabetic retinopathy (DR). THR-149, a plasma kallikrein inhibitor, and TB-403, an anti-PlGF, are also being developed for the treatment of different eye conditions. The company has collaboration agreements with various other pharmaceutical companies, including BioInvent International AB, Bicycle Therapeutics, Outcome Sciences, Inc., Parexel, INC Research, Galapagos, and Beta Therapeutics Pty Ltd. Oxurion NV was previously known as ThromboGenics NV but changed its name to Oxurion NV in September 2018. Founded in 1991, this Leuvener-based company has its main website accessible under www.oxurion.com and is listed on the NYSE Euronext Brussels stock exchange.